首頁 > 市場調查報告書 > 醫療設備

眼科設備手術用器具

市場調查報告書

商品編碼

1345394

全球圓錐角膜治療市場 - 2023-2030

Global Keratoconus Treatment Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

2022年，全球圓錐角膜治療市場達到5億美元，預計到2030年將達到6億美元，預測期內（2023-2030年）年複合成長率為3.9%。

圓錐角膜是一種視力疾病，當通常為圓形的角膜變薄且不均勻（圓錐形）時，會導致穿透眼睛的光線無法準確地集中在視網膜上並導致視力扭曲。通常，圓錐角膜出現在雙眼中並影響中央角膜，圓錐頂位於視軸下方。每 100,000 人中大約有 50 至 200 人患有圓錐角膜。

眼睛相關問題的案例不斷增加，研究舉措不斷增加，合作、產品批准等市場發展；研究活動和技術進步等因素預計將推動預測期內全球圓錐角膜治療市場的成長。

動力學

不斷成長的市場發展推動了圓錐角膜治療市場的成長。

市場的不斷發展預計將推動預測期內全球圓錐角膜治療市場的成長。例如，2022 年8 月，Glaukos、眼科醫療技術和製藥公司專注於治療角膜疾病、青光眼和視網膜疾病的新療法，與iVeena Delivery Systems 簽訂了戰略許可契約，iVeena Delivery Systems 是一家私人持有的臨床階段藥物。眼科公司設計非手術、非侵入性藥理創新，使 Glaukos 獲得全球唯一同意設計和商業化用於圓錐角膜治療的 IVMED-80。

此外，2023年7月，眼保健品公司博士倫以1.065億美元的決定價格從強生公司子公司Johnson & Johnson Vision收購了Blink非處方（OTC）滴眼液系列。此次最新收購進一步堅定了該公司堅持通過 OTC 眼部護理開發來提高客戶舒適度的決心。

支持圓錐角膜治療的舉措不斷增加，預計將為全球圓錐角膜治療市場帶來成長機會。

支持圓錐角膜治療的舉措不斷增加，預計將為全球圓錐角膜治療市場在未來幾年帶來潛在的成長機會。例如，全球圓錐角膜教育計劃為您提供在實踐中治療圓錐角膜所需的一切資訊，包括圓錐角膜電子資源- 現代圓錐角膜管理的綜合指南、關於在臨床實踐中識別和管理圓錐角膜的網路研討會。

預計缺乏認知將在預測期內阻礙全球圓錐角膜治療市場。

缺乏認知預計將阻礙全球圓錐角膜治療市場的成長。例如，許多與眼睛有關的問題是逐漸發生的，並且是由於疏忽而引起的。其中一些問題是最小的，而另一些則需要昂貴的某些治療方法。在徹底發展的地區，相當多的人沒有足夠的錢來選擇治療這些疾病。同樣，他們中的大多數人對這些條件缺乏足夠的了解，這進一步加劇了嚴酷性。

有關此報告的更多詳細資訊 - 索取樣品

Overview

The global Keratoconus Treatment market reached US$ 0.5 billion in 2022 and is expected to reach US$ 0.6 billion by 2030, exhibiting a CAGR of 3.9% during the forecast period (2023-2030).

Keratoconus is an eyesight condition that transpires when the commonly round cornea becomes thin and uneven (cone) shaped, preventing the light penetrating the eye from being concentrated accurately on the retina and causing contortion of vision. Usually, keratoconus appears in both eyes and affects the central cornea with the peak of the cone just under the visual axis. Roughly 50 to 200 of every 100,000 individuals are afflicted with keratoconus.

The growing cases of eye-related problems, increasing research initiatives, market developments such as collaborations, product approvals, and other; research activities, and technological advancements among other factors are expected to boost the global Keratoconus Treatment market growth in the forecast period.

Dynamics

Increasing Market Developments Drive the Growth of the Keratoconus Treatment Market.

Increasing market developments are expected to boost the global keratoconus treatment market growth in the forecast period. For instance, in August 2022, Glaukos, ophthalmic medical technology, and pharmaceutical corporation that concentrated on novel treatments for the therapy of corneal disorders, glaucoma, and retinal disorders constituted a strategic licensing contract with iVeena Delivery Systems, a privately held, clinical-stage ophthalmology corporation designing non-surgical, non-invasive, pharmacologic innovations giving Glaukos a sole global consent to design and commercialize IVMED-80 for the therapy of keratoconus.

Moreover, in July 2023, Bausch + Lomb, an eye health products corporation acquired the Blink over-the-counter (OTC) line of eye drops from Johnson & Johnson Vision, a subsidiary of Johnson & Johnson for the decided cost of USD 106.5 million. This most current acquisition adds to the corporation's affirmation to persist in increasing customer comfort with OTC eye care developments.

The Increasing initiatives to support the keratoconus treatment are Expected to Present the Global Keratoconus Treatment Market With Growth Opportunities.

The increasing initiatives to support the keratoconus treatment are expected to present the global keratoconus treatment market with prospective growth opportunities in the forthcoming years. For instance, the global Keratoconus Education Initiative provides you with everything you need to know to treat keratoconus in your practice including, the Keratoconus eResource- a comprehensive guide to the modern Management of Keratoconus, webinar on identifying and managing keratoconus in clinical practice.

The Lack of Awareness is Estimated to Hamper the Global Keratoconus Treatment Market During the Forecast Period.

The lack of awareness is estimated expected to hamper the global keratoconus treatment market growth. For instance, numerous eye-related issues grow very gradually and are induced because of negligence. Some of these concerns are tiniest, while some require certain therapies that are costly. In thoroughly evolving regions, a considerable number of individuals do not have sufficient money to opt for therapy for these conditions. Again, a majority of them have an insufficient understanding regarding such conditions that, additionally advance the harshness.

For more details on this report - Request for Sample

Segment Analysis

The global keratoconus treatment market is segmented based on type, treatment type, end-users, and region.

The Surgical Treatment Type Segment of Keratoconus Treatment is Estimated to Dominate the Global Keratoconus Treatment Market.

The surgical treatment type segment of the keratoconus treatment is expected to hold around 27.8% of the global market share owing to the increasing research activities. For instance, in January 2023, Glaukos, ophthalmic medical technology, and pharmaceutical corporation that concentrated on novel treatments for the therapy of corneal disorders, glaucoma, and retinal disorders declared the positive outcomes for a forthcoming, multi-center clinical investigation devised to assess the safeness of the surgical exchange approach for travoprost intraocular implant in individuals who had already obtained a travoprost intraocular implant in the Phase 2b clinical trial, also called the exchange trial.

Furthermore, the increasing initiatives in the surgical treatment type also contribute to segment growth. For instance, in April 2023, Michael W. Belin, MD, CMO of CXL Ophthalmics, Inc., a clinical-stage corporation designing a minimally invasive keratoconus therapy, is expected to provide the Plenary Session at the first International Keratoconus Academy (IKA) Symposium. The meeting is expected to get joint optometrists, ophthalmologists, and industry professionals curious about the administration and therapy of keratoconus.

Ggeographical Penetration

North America is estimated to hold Approximately 38.3% of the Market Share by 2030, Owing to Market Developments in this Region.

Owing to the increasing market developments in the North American region, it is estimated to dominate the global market holding around 38.3% of the market by 2030. For instance, For instance, in November 2022, CooperVision added SynergEyes to its CooperVision professional eye care industry segment, intensifying its promise to promote the usage of professional contact lenses in North America and almost the globe. The mixed lens approaches and trademarks presented by the Carlsbad, California-based corporation cover the therapy of uneven cornea, presbyopia, and astigmatism.

Furthermore, the increasing research activities on keratoconus also contribute to the regional market growth in the forecast period. For instance, the investigators at the North Texas Eye Research Institute recognized, separated, and characterized tear EVs (tEVs) in keratoconus patients and discovered that they have a different phenotype corresponding to their healthy counterparts. In the investigation, 10 healthy subjects and nine keratoconus-diagnosed individuals were analyzed. Men with eye disorders were also discovered to have more elevated total counts of tEVs than females.

Competitive Landscape

The major global players in the keratoconus treatment market include: Sandoz International GmbH, HOYA, Menicon Co., Ltd., The Cooper Companies, Inc., Bausch Health Companies Inc., SynergEyes, Carl Zeiss Meditec AG, Contamac, SEED Co., Ltd, Novartis AG, and Johnson & Johnson Services, Inc., among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is assumed to have had a moderate impact on the global keratoconus treatment market, as during the 3 months of full-scale warfare, Russians sabotaged over 600 infirmaries and massacred at least 12 medics. Access to health care is majorly affected because of security considerations, limited mobility, damaged supply chains, and mass population eviction. Also, the lack of primary market players in this region. In addition to it, the significance of the import and export of fundamental materials are expected to slightly impact the global Keratoconus Treatment market growth in the forecast period.

By Type

Corneal Hydrops
Forme Fruste Keratoconus
Posterior Keratoconus
Keratoglobus
Pellucid Marginal Degeneration

By Treatment Type

Lenses
Therapies
Surgery
Others

By End-Users

Hospitals
Homecare
Specialty Clinics
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Key Developments

In May 2023, Menicon Co., Ltd. declared that Itabashi Medical (Dalian) Co., Ltd., a Chinese affiliate, launched "ROSE K" in China in April 2023. A hard contact lens for keratoconus individuals is called ROSE K.
In September 2022, CXL Ophthalmics, Inc., a clinical-stage corporation designing a minimally-invasive treatment for keratoconus, declared positive outcomes of the EpiSmart cross-linking Phase 2 study for keratoconus in Cornea.
In September 2022, CXL Ophthalmics, Inc., a clinical-stage corporation designing a minimally-invasive treatment for keratoconus, secured a $32 million Series A funding round led by AXA IM Alts through its Global Health Private Equity approach plus a syndicate of individual investors, including leading cornea specialists.

Why Purchase the Report?

To visualize the global keratoconus treatment market segmentation based on type, treatment type, end-users, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous keratoconus treatment market-level data points with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available in excel consisting of key products of all the major players.

The global keratoconus treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Treatment Type
3.3. Snippet by End-Users
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Market Developments
  - 4.1.1.2. Research Advancements
- 4.1.2. Restraints
  - 4.1.2.1. Lack of Awareness
- 4.1.3. Opportunity
  - 4.1.3.1. Increasing Initiatives
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Corneal Hydrops*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Forme Fruste Keratoconus
7.4. Posterior Keratoconus
7.5. Keratoglobus
7.6. Pellucid Marginal Degeneration

8. By Treatment Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Lenses*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Therapies
8.4. Surgery
8.5. Others

9. By End-Users

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 9.1.2. Market Attractiveness Index, By End-Users
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Homecare
9.4. Specialty Clinics
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. The U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Spain
  - 10.3.6.5. Italy
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan

Australia

10.5.6.4. Rest of Asia-Pacific

10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Sandoz International GmbH*
- 12.1.1. Company Overview
- 12.1.2. Type Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. HOYA
12.3. Menicon Co., Ltd.
12.4. The Cooper Companies, Inc.
12.5. Bausch Health Companies Inc.
12.6. SynergEyes
12.7. Carl Zeiss Meditec AG
12.8. Contamac
12.9. SEED Co., Ltd
12.10. Novartis AG
12.11. Johnson & Johnson Services, Inc.